RSS Feeds
Search

Companies

Innopharmax Inc.

Innopharmax Inc.
INNOPHARMAX is a specialty pharmaceutical company focused in the treatment of infectious diseases,immunology and oncology via DDS technology to improve safety & effectivene of currently available drug

The company in detail

Profile

INNOPHARMAX is a specialty pharmaceutical company that focuses on the development and commercialization of products that are indicated for infectious diseases, immunology and oncology. We internally develop and/or acquire potential drug candidates for further clinical development as well as commercialization. By utilizing the internally developed drug delivery technology platforms, we aim to improve the safety and effectiveness of currently available drugs. Following that, INNOPHARMAX is well positioned to provide better medical choices in the above-mentioned disease categories. Based on our strong formulation know-how and strategical global partnership establishment, INNOPHARMAX is committed to deliver superior pharmaceutical products cost-effectively with global quality standards to meet our clients' needs. 

Partnering strategy/interests

INNOPHARMAX values its partners and continues to seek out new business opportunities. If parttners are interested in the areas of,

  • Business Development (in or out licensing)
  • Supply (API, excipients, etc.)

 

 

 

 

 

 

Out-licensing

Bestnem(Imipenem and cilastatin ) More
MRI contast medium More
immuno-suppresant agent More
A combination drug of three active ingredients for the treatment of Parkinson’s disease More
Inno-C08001 is indicated for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction More
Unique oral formulation on gmecitabine with Oral PAS technology More

Press Releases

(1st Apr 2013) Innopharmax announces its participation in BIO International Convention 2013 in Chicago(4/22-25). Booth number: 4878 More
More press releases

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us